Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2009

01-04-2009 | Epidemiology

Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history

Authors: Megan L. Welsh, Diana S. M. Buist, Erin J. Aiello Bowles, Melissa L. Anderson, Joann G. Elmore, Christopher I. Li

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

Objective Many studies that have estimated the breast cancer risk attributable to family history have been based on data collected within family units. Use of this study design has likely overestimated risks for the general population. We provide population-based estimates of breast cancer risk and different tumor subtypes in relation to the degree, number, and age at diagnosis of affected relatives. Methods Cox Proportional Hazards to calculate risks (hazard ratios; 95% confidence interval) of breast cancer and tumor subtypes for women with a family history of breast cancer relative to women without a family history among a cohort of 75,189 women age ≥40 years of whom 1,087 were diagnosed with breast cancer from June 1, 2001–December 31, 2005 (median follow-up 3.16 years). Results Breast cancer risk was highest for women with a first-degree family history (1.54; 1.34–1.77); and did not differ substantially by the affected relative’s age at diagnosis or by number of affected first-degree relatives. A second-degree family history only was not associated with a significantly increased breast cancer risk (1.15; 0.98–1.35). There was a suggestion that a positive family history was associated with risk of triple positive (Estrogen+/Progesterone+/HER2+) and HER2-overexpressing tumors. Conclusions While a family history of breast cancer in first-degree relatives is an important risk factor for breast cancer, gathering information such as the age at diagnosis of affected relatives or information on second-degree relative history may be unnecessary in assessing personal breast cancer risk among women age ≥40 years.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sattin RW, Rubin GL, Webster LA et al (1985) Family history and the risk of breast cancer. JAMA 253(13):1908–1913PubMedCrossRef Sattin RW, Rubin GL, Webster LA et al (1985) Family history and the risk of breast cancer. JAMA 253(13):1908–1913PubMedCrossRef
2.
go back to reference Colditz GA, Willett WC, Hunter DJ et al (1993) Family history, age and risk of breast cancer: prospective data from the nurses’ health study. JAMA 270(3):338–343PubMedCrossRef Colditz GA, Willett WC, Hunter DJ et al (1993) Family history, age and risk of breast cancer: prospective data from the nurses’ health study. JAMA 270(3):338–343PubMedCrossRef
3.
go back to reference Parazzini F, La Vecchia C, Negri E et al (1993) Family history of breast, ovarian and endometrial cancer and risk of breast cancer. Int J Epidemiol 22(4):614–618PubMedCrossRef Parazzini F, La Vecchia C, Negri E et al (1993) Family history of breast, ovarian and endometrial cancer and risk of breast cancer. Int J Epidemiol 22(4):614–618PubMedCrossRef
4.
go back to reference Muhonen T, Eerola H, Vehmanen P et al (1997) Breast cancer risk estimation in families with history of breast cancer. Br J Cancer 76(9):1228–1231PubMed Muhonen T, Eerola H, Vehmanen P et al (1997) Breast cancer risk estimation in families with history of breast cancer. Br J Cancer 76(9):1228–1231PubMed
5.
go back to reference Negri E, Braga C, La Vecchia C et al (1997) Family history of cancer and risk of breast cancer. Int J Cancer 72(5):735–738PubMedCrossRef Negri E, Braga C, La Vecchia C et al (1997) Family history of cancer and risk of breast cancer. Int J Cancer 72(5):735–738PubMedCrossRef
6.
go back to reference Pharoah PDP, Day NE, Duffy S et al (1997) Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 71(5):800–809PubMedCrossRef Pharoah PDP, Day NE, Duffy S et al (1997) Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 71(5):800–809PubMedCrossRef
7.
go back to reference Anderson H, Bladström A, Olsson H et al (2000) Familial breast and ovarian cancer: a Swedish population-based register study. Am J Epidemiol 152(12):1154–1163PubMedCrossRef Anderson H, Bladström A, Olsson H et al (2000) Familial breast and ovarian cancer: a Swedish population-based register study. Am J Epidemiol 152(12):1154–1163PubMedCrossRef
8.
go back to reference Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med 9(1):208–221PubMedCrossRef Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med 9(1):208–221PubMedCrossRef
9.
go back to reference Hopper JL, Bishop DT, Easton DF (2005) Population-based family studies in genetic epidemiology. Lancet 366(9494):1397–1406PubMedCrossRef Hopper JL, Bishop DT, Easton DF (2005) Population-based family studies in genetic epidemiology. Lancet 366(9494):1397–1406PubMedCrossRef
10.
go back to reference Crest AB, Aiello EJ, Anderson ML et al (2006) Varying levels of family history of breast cancer in relation to mammographic breast density (United States). Cancer Causes Control 17(6):843–850PubMedCrossRef Crest AB, Aiello EJ, Anderson ML et al (2006) Varying levels of family history of breast cancer in relation to mammographic breast density (United States). Cancer Causes Control 17(6):843–850PubMedCrossRef
11.
go back to reference Lehrer S, Lee P, Tartter P et al (1995) Breast cancer and family history: a multivariate analysis of levels of tumor HER2 protein and family history of cancer in women who have breast cancer. Mt Sinai J Med 62(6):415–418PubMed Lehrer S, Lee P, Tartter P et al (1995) Breast cancer and family history: a multivariate analysis of levels of tumor HER2 protein and family history of cancer in women who have breast cancer. Mt Sinai J Med 62(6):415–418PubMed
12.
go back to reference Tutera AM, Sellers TA, Potter JD et al (1996) Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status. Genet Epidemiol 13(2):207–221PubMedCrossRef Tutera AM, Sellers TA, Potter JD et al (1996) Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status. Genet Epidemiol 13(2):207–221PubMedCrossRef
13.
go back to reference Huang WY, Newman B, Millikan RC et al (2000) Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev 9(1):65–71PubMed Huang WY, Newman B, Millikan RC et al (2000) Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev 9(1):65–71PubMed
14.
go back to reference Gavrilov I, Nacheva M, Tzingilev D (2002) Familial breast cancer. Part II: relationships with histology, staging, steroid receptors and serum tumor markers. J BUON 7(1):61–65PubMed Gavrilov I, Nacheva M, Tzingilev D (2002) Familial breast cancer. Part II: relationships with histology, staging, steroid receptors and serum tumor markers. J BUON 7(1):61–65PubMed
15.
go back to reference Yang XR, Sherman ME, Rimm DL et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439–443PubMedCrossRef Yang XR, Sherman ME, Rimm DL et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439–443PubMedCrossRef
16.
go back to reference Althuis MD, Fergenbaum JH, Garcia-Closas M et al (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13(10):1558–1568PubMed Althuis MD, Fergenbaum JH, Garcia-Closas M et al (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13(10):1558–1568PubMed
17.
go back to reference Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874PubMedCrossRef Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874PubMedCrossRef
18.
go back to reference Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502PubMedCrossRef Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502PubMedCrossRef
19.
go back to reference Taplin SH, Thompson RS, Schnitzer F et al (1990) Revisions in the risk-based Breast Cancer Screening Program at Group Health Cooperative. Cancer 66(4):812–818PubMedCrossRef Taplin SH, Thompson RS, Schnitzer F et al (1990) Revisions in the risk-based Breast Cancer Screening Program at Group Health Cooperative. Cancer 66(4):812–818PubMedCrossRef
20.
go back to reference Taplin SH, Mandelson MT, Anderman C et al (1997) Mammography diffusion and trends in late-state breast cancer: evaluating outcomes in a population. Cancer Epidemiol Biomarkers Prev 6(8):625–631PubMed Taplin SH, Mandelson MT, Anderman C et al (1997) Mammography diffusion and trends in late-state breast cancer: evaluating outcomes in a population. Cancer Epidemiol Biomarkers Prev 6(8):625–631PubMed
21.
go back to reference Taplin SH, Ichikawa L, Buist DS et al (2004) Evaluating organized breast cancer screening implementation: the prevention of late-state disease? Cancer Epidemiol Biomarkers Prev 13(2):225–234PubMedCrossRef Taplin SH, Ichikawa L, Buist DS et al (2004) Evaluating organized breast cancer screening implementation: the prevention of late-state disease? Cancer Epidemiol Biomarkers Prev 13(2):225–234PubMedCrossRef
23.
go back to reference Cox DR, Oakes D (1984) Analysis of survival data. Chapman & Hall, London Cox DR, Oakes D (1984) Analysis of survival data. Chapman & Hall, London
24.
go back to reference Perou CM, Sørlie T, Elsen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef Perou CM, Sørlie T, Elsen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef
25.
go back to reference Sørlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418–8423PubMedCrossRef Sørlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418–8423PubMedCrossRef
26.
go back to reference American College of Radiology (2003) Breast imaging reporting and data system (BI-RADS™), 4th edn. American College of Radiology, Reston, VA American College of Radiology (2003) Breast imaging reporting and data system (BI-RADS™), 4th edn. American College of Radiology, Reston, VA
27.
go back to reference Hosmer DW, Lemeshow S (1999) Applied Survival analysis: regression modeling of time to event data. John Wiley, Inc., New York Hosmer DW, Lemeshow S (1999) Applied Survival analysis: regression modeling of time to event data. John Wiley, Inc., New York
28.
go back to reference StataCorp (2005) Stata statistical software: release 9. StataCorp LP, College Station, TX StataCorp (2005) Stata statistical software: release 9. StataCorp LP, College Station, TX
29.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef
30.
go back to reference Calle EE, Martin LM, Thun MJ et al (1993) Family history, age, and risk of fatal breast cancer. Am J Epidemiol 138(9):675–681PubMed Calle EE, Martin LM, Thun MJ et al (1993) Family history, age, and risk of fatal breast cancer. Am J Epidemiol 138(9):675–681PubMed
31.
go back to reference Ziogas A, Anton-Culver H (2003) Validation of family history data in cancer family registries. Am J Prev Med 24(2):190–198PubMedCrossRef Ziogas A, Anton-Culver H (2003) Validation of family history data in cancer family registries. Am J Prev Med 24(2):190–198PubMedCrossRef
32.
go back to reference Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292(12):1480–1489PubMedCrossRef Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292(12):1480–1489PubMedCrossRef
33.
go back to reference Coliditz GA, Rosner BA, Chen WY et al (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96(3):218–228CrossRef Coliditz GA, Rosner BA, Chen WY et al (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96(3):218–228CrossRef
34.
go back to reference Swede H, Moysich KB, Freudenheim JL et al (2001) Breast cancer risk factors and HER2 over-expression in tumors. Cancer Detect Prev 25(6):511–519PubMed Swede H, Moysich KB, Freudenheim JL et al (2001) Breast cancer risk factors and HER2 over-expression in tumors. Cancer Detect Prev 25(6):511–519PubMed
35.
go back to reference Cooper JA, Rohan TE, Cant EL et al (1989) Risk factors for breast cancer by oestrogen receptor status: a population-based case–control study. Br J Cancer 59(1):119–125PubMed Cooper JA, Rohan TE, Cant EL et al (1989) Risk factors for breast cancer by oestrogen receptor status: a population-based case–control study. Br J Cancer 59(1):119–125PubMed
36.
go back to reference Lakhani SR, Van De Vijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318PubMedCrossRef Lakhani SR, Van De Vijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318PubMedCrossRef
37.
go back to reference Sellers TA, Kushi LH, Potter JD et al (1993) Effect of family history, body-fat distribution, and reproductive factors on the risk of postmenopausal breast cancer. N Engl J Med 326(20):1323–1329 Sellers TA, Kushi LH, Potter JD et al (1993) Effect of family history, body-fat distribution, and reproductive factors on the risk of postmenopausal breast cancer. N Engl J Med 326(20):1323–1329
38.
go back to reference Yankaskas BC (2005–2006) Epidemiology of breast cancer in young women. Breast Dis 23(1):3–8 Yankaskas BC (2005–2006) Epidemiology of breast cancer in young women. Breast Dis 23(1):3–8
40.
go back to reference Hall IJ, Burke W, Coughlin S et al (2001) Population-based estimates of the prevalence of family history of cancer among women. Community Genet 4(3):134–142PubMedCrossRef Hall IJ, Burke W, Coughlin S et al (2001) Population-based estimates of the prevalence of family history of cancer among women. Community Genet 4(3):134–142PubMedCrossRef
Metadata
Title
Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history
Authors
Megan L. Welsh
Diana S. M. Buist
Erin J. Aiello Bowles
Melissa L. Anderson
Joann G. Elmore
Christopher I. Li
Publication date
01-04-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0026-1

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine